Campath (alemtuzumab) / Bayer, Sanofi - LARVOL DELTA

Incorporation of 8Gy total body irradiation into reduced intensity conditioning does not improve allogeneic transplant outcomes for high-risk adult acute lymphoblastic leukemia: Results from the randomised prospective phase 2 UK multicentre ALL-RIC impact study (ASH 2025) - "We therefore performed a prospective,randomised comparison of the UK FMA RIC regimen with a cyclophosphamide plus 8Gy TBI RIC protocol(Cy/8TBI), with the goal of improving OS in high-risk adult ALL.MethodsThe FMA RIC regimen (fludarabine 30mg/m2 IV for 5d; melphalan 140mg/m2 IV single dose; alemtuzumab 30mg IV D-1 for sibling donor/20mg IV D-2 & -1 for unrelated donor) was compared tocyclophosphamide 50mg/kg for 2d plus 8Gy TBI (4# over 2d) and alemtuzumab (dosed as per FMA).Intrathecal prophylaxis was given for 2y post-SCT. However, incorporation of 8Gy TBI into a RIC protocol designed for older adults was welltolerated, with no increases in acute or chronic GvHD, and no additional infectious or extramedullarytoxicity.These data highlight the importance of performing randomised trials of innovative conditioningregimens, if outcomes for older patients receiving allo-SCT for ALL are to be improved. Importantly theALL-RIC trial showcases feasibility and patient..."

Clinical • P2 data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • T Acute Lymphoblastic Leukemia • Transplantation • KMT2A

FIRST REPORTED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR RAD50 DEFICIENCY: INITIAL CLINICAL EXPERIENCE IN TWO PEDIATRIC PATIENTS (EBMT 2026) - "Within one year, bone marrow dysplasia with a del(5q) clone and blasts up to 6–7% evolved, consistent with MDS on the background of inborn error of immunity.Unrelated-donor allo-HSCT (conditioning regimen: fludarabine 150 mg/m², busulfan 4 mg/kg, ATG 5 mg/kg and rituximab 375 mg/m², with PTCy-based GVHD prophylaxis) was complicated by HHV-6 infection, severe infusion-associated rash, and subsequent graft rejection by day +60. Six months later a second haploidentical HSCT from the mother (conditioning regimen: fludarabine 150 mg/m², treosulfan 21 g/m², rituximab 375 mg/m² and alemtuzumab 0.4 mg/kg with PTCy-based GVHD prophylaxis) resulted in timely engraftment and was complicated by megakaryocytic lineage hypofunction, viral reactivation, COVID-19 infection, and mild skin GVHD.Case #2...The course was marked by transfusion dependence, recurrent infections and refractory thrombocytopenia despite romiplostim and eltrombopag therapy.At the age of..."

Clinical • Acute Kidney Injury • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Herpes Simplex • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pediatrics • Thrombocytopenia • Transplant Rejection • Transplantation • RAD50

Nonmyeloablative Conditioning Decreases Toxicity with Comparable Cure Rate In Pediatric MSD HCT for Sickle Cell Disease (TCT-ASTCT-CIBMTR 2026) - P2 | "MAC patients received busulfan-based regimens. RIC patients received alemtuzumab, fludarabine, melphalan, ± thiotepa...Conclusion In pediatric MSD HCT for SCD, NMA conditioning with alemtuzumab, low-dose TBI, and sirolimus effectively decreases toxicity compared to MAC and RIC, with comparable cure rates. Although some patients require second HCT for declining chimerism, overall outcomes support NMA as a viable option for children and adolescents with SCD."

Clinical • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Sickle Cell Disease

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure (clinicaltrials.gov) - P1/2 | N=8 | Recruiting | Sponsor: Paul Szabolcs | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Aplastic Anemia • Bone Marrow Transplantation • Chronic Obstructive Pulmonary Disease • Hematological Disorders • Idiopathic Pulmonary Fibrosis • Immunology • Neutropenia • Pulmonary Disease • Respiratory Diseases • Transplantation

Eculizumab Is Associated with Significantly Lower Adenovirus Clearance in Children after Hematopoietic Cell Transplantation (TCT-ASTCT-CIBMTR 2026) - " Among 25 children with adenoviremia, the first adenovirus PCR was detected a median of 62 days post-HCT, Treatment approaches included cidofovir (76%), reduction of immune suppression (32%), viral specific T cells (20%), and brincidofovir (8%)- all ecu exposed patients received ≥1 treatment and 50% of non-ecu exposed received ≥1 treatment...In bivariable models adjusting for alemtuzumab (HR 0.26, p=0.02), abatacept (HR 0.14, p=0.001), post-HCT cyclophosphamide (HR 0.28, p=0.02), grade 3-4 acute GVHD (HR 0.20, p=0.02), and absolute lymphocyte count at first adenovirus PCR (HR 0.29, p=0.02), adenovirus clearance remained significantly lower in than those exposed to ecu... In this single center retrospective study, eculizumab exposed children were 3 times less likely to clear adenovirus and 6 times more likely to die of adenovirus related mortality. While these findings need to be validated in larger cohorts, our findings merit a careful risk/benefit analysis prior to..."

Clinical • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation • Transplantation Associated Thrombotic Microangiopathy

Reversing Mixed Chimerism in Sickle Cell Disease: A Case for Extended Immunosuppression Following Allogeneic Hematopoietic Stem Cell Transplant (TCT-ASTCT-CIBMTR 2026) - "She received a reduced- intensity conditioning regimen (RIC) of Campath, Fludarabine, Thiotepa, and Melphalan. GVHD prophylaxis included Tacrolimus, Mycophenolate Mofetil, and Abatacept...Explain clinical and lab indications of graft failure or disease recurrence in patients with sickle cell disease following stem cell transplant 3. Describe the role of immunosuppression as a tool to manage faltering chimerism post transplant"

Clinical • Bone Marrow Transplantation • Cardiovascular • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Sickle Cell Disease • Transplantation

Comparison of Viral Infection Rates after T-cell Depletion in Pediatric HCT: Alemtuzumab Vs Post-Transplant Cyclophosphamide (TCT-ASTCT-CIBMTR 2026) - "The alemtuzumab group was younger (median 7.7 vs 13.9 years) and, as expected, primarily received MUD transplants (85%), while the PTCy group mainly received haploidentical transplants (63%); letermovir use was similar between groups (Table 1). In this pediatric HCT cohort, viral infection rates were comparable between alemtuzumab and PTCy. Despite the small sample size, both T-cell depletion approaches appear to pose comparable infectious risks, supporting tailored platform choice based on donor and clinical factors. 1."

Clinical • Post-transplantation • Infectious Disease • Pediatrics • Transplantation

Radiation-Free Reduced-Intensity Conditioning Achieves Excellent Outcomes in Pediatric Severe Aplastic Anemia (TCT-ASTCT-CIBMTR 2026) - "Most had fully matched donors (83%), and 58% received alemtuzumab, fludarabine, and melphalan. Conclusions Radiation-free conditioning is safe, well-tolerated, and effective in pediatric sAA, achieving robust engraftment, durable donor chimerism, and survival comparable or superior to TBI-based regimens, while avoiding late radiation toxicities. Review conditioning regimens used for the treatment of pediatric patients with severe aplastic anemia in stem cell transplant Review short term outcomes in patients with severe aplastic anemia treated with radiation-free conditioning regimens Compare outcomes using radiation-free conditioning regimens to other studies in which radiation was used as part of conditioning for patients with severe aplastic anemia"

Clinical • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplant Rejection • CD4 • CD8

Post-Transplant Cyclophosphamide with Extended Abatacept for GVHD Prophylaxis Following Haploidentical Transplantation for Non-Malignant Disorders (TCT-ASTCT-CIBMTR 2026) - "Conditioning included alemtuzumab (total 33 mg if 10 kg) days -22 to -19, fludarabine (total 150 mg/m2) days -8 to -4, thiotepa 8 mg/kg day -4, and melphalan (140 mg/m2) day -3. Sickle cell disease (SCD) patients also received hydroxyurea (30 mg/kg/d) from days -60 to -21...One EBV-PTLD case required rituximab and early abatacept cessation (day +118)...3. Describe expected immune reconstitution."

Post-transplantation • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Sickle Cell Disease • Transplantation • CD4 • IL2RA • IL7R

Donor Lymphocyte Infusion in Myeloid Malignancies: Reassessing Predictors of Response (TCT-ASTCT-CIBMTR 2026) - "T-cell Deplete HCT: OS was 61.7% for T-cell deplete (n = 35 [PTCY n =12, CD45RA- n = 12, ATG/Campath n = 11]) and 54.0% for T-cell replete HCT (p = 0.309)... CD33 chimerism < 90% and ≥ 1% malignant BM blasts are risk factors for DLI failure. For patients receiving DLI in remission, prior overt relapse (vs. MRD only) and MRD+ pre-DLI status were numerically associated with worse outcomes."

Chronic Myelomonocytic Leukemia • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Preventive care • CD33

Post-Transplant Cyclophosphamide Is Associated with Improved Overall Survival and Reduced Non-Relapse Mortality When Compared with Alemtuzumab in Patients Undergoing Allogeneic Transplantation with Reduced-Intensity Conditioning: A Single Center Retrospective Analysis (TCT-ASTCT-CIBMTR 2026) - "However, more patients required treatment of adenoviremia with cidofovir 8 (alem) vs 1 (PTCy), p = 0.032, and led to death in 6 patients (all alem). Findings from this retrospective study indicate that PTCy-based GVHD ppx exhibits improved OS and reduced NRM. Infections due to poor or delayed immune reconstitution in the alem cohort may contribute to this increased mortality. 1."

Post-transplantation • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Outcomes of Gene Therapy and Allogeneic Hematopoietic Cell Transplantation for Sickle Cell Disease: A Single-Center Retrospective Analysis (TCT-ASTCT-CIBMTR 2026) - "14 pts with sickle cell anemia (SCA) underwent 15 cellular therapies at our center, including 7 GT (lovo-cel via HGB-206/210 trials) and 8 alloHCT (3 haploidentical donors (haplo) and 5 matched-related donor (MRD))...Graft failure occurred in 2 alloHCT compared to 0 in GT, both in pts who received non-myeloablative conditioning (alemtuzumab/total body irradiation) for MRD alloHCT with 1 patient then proceeding to a second MRD alloHCT...Gene therapy and allogeneic cell transplantation offer durable engraftment and hemoglobin S suppression in sickle cell anemia. Survival, hospital length-of-stay, and infectious complications were similar between treatment groups in our study."

Gene therapy • Retrospective data • Addiction (Opioid and Alcohol) • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Mucositis • Neutropenia • Retinal Disorders • Septic Shock • Sickle Cell Disease • Transplantation

Autoimmunity in Patients with Wiskott-Aldrich Syndrome (WAS) after Hematopoietic Stem Cell Transplantation (HSCT)- a Single Center Experience (TCT-ASTCT-CIBMTR 2026) - "Myeloablative conditioning (MAC) was defined as regimens that contained busulfan AUC ≥50 mg x h/L combined with cyclophosphamide and ATG (used at our institute prior to 2015) and reduced intensity conditioning (RIC) was defined as busulfan cumulative AUC <80 mg x h/L combined with fludarabine and alemtuzumab (after 2015)...Two patients (29%) had a relapsing–remitting course: one with colitis requiring ongoing infliximab (onset 8 months, on therapy ~2 years), and one with autoimmune hemolytic anemia on sirolimus (onset 17 months, on therapy ~3 years)...3. To describe the implications of persistent autoimmunity manifestations."

Clinical • Acute Graft versus Host Disease • Autoimmune Hemolytic Anemia • Bone Marrow Transplantation • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Primary Immunodeficiency • Transplantation

Improved Stem Cell Transplant Survival in Pediatric Inborn Errors of Metabolism (IEM) after 2010: A Single Center Experience of the Impact of Cord Blood Utilization and Conditioning Approach (TCT-ASTCT-CIBMTR 2026) - "While CBT performed after 2010 did not use serotherapy (Alemtuzumab/ATG), it was used in 57% of transplants (n=19)... Survival outcomes for pediatric patients with IEM have markedly improved since 2010. Earlier transplant referral, refined conditioning regimens, and expanded use of CBT may be contributing to improvements, as CBT offers rapid donor availability and shortens time to transplant, limiting disease progression and irreversible organ damage. While graft failure can be a challenge, these results suggest that CBT is a strong alternative donor source and highlight the need for continued optimization of timing and conditioning to achieve durable, long-term cure."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Immunology • Metabolic Disorders • Pediatrics • Transplantation

Retrospective Application of Population Pharmacokinetic Model-Based Dosing for Fludarabine in Allogeneic Hematopoietic Cell Transplant for Inborn Errors of Immunity (TCT-ASTCT-CIBMTR 2026) - " The cohort included 37 patients: 25 recipients of reduced toxicity myeloablative conditioning (alemtuzumab, busulfan, fludarabine) and 12 recipients of reduced intensity conditioning (alemtuzumab, melphalan, and fludarabine). Confirmation of fludarabine over-exposure association with delayed immune reconstitution in a single-center retrospective cohort undergoing HCT for IEI provides further support for implementation of clinically impactful pop-PK guided dosing of conditioning. Fludarabine over-exposure is associated with delayed immune reconstitution following transplant for IEI. Fludarabine dosing by body-surface-area alone routinely results in overexposure."

PK/PD data • Retrospective data • Transplantation • CD4

Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia. (PubMed, N Engl J Med) - "Universal BE-CAR7 T cells induced leukemic remission in patients with relapsed or refractory T-cell ALL, thus allowing successful allogeneic hematopoietic stem-cell transplantation in most of the patients. (Funded by the Medical Research Council and others; ISRCTN Registry number, ISRCTN15323014.)."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Palliative care • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • Transplantation • CD52

Medication-associated thyroid eye disease: a review. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "Medication-associated TED is an important differential consideration in the work-up of orbital inflammatory disease. The clinico-radiological manifestations and the principles of management of medication-associated TED were similar to that of de novo TED. Certain medications, such as various ICIs, may demonstrate different clinical phenotypes of orbital inflammation, inciting either TED or a "TED-like" orbitopathy without evidence of underlying thyroid dysfunction."

Journal • Review • Endocrine Disorders • Grave’s Disease • Inflammation • Ocular Inflammation • Oncology • Ophthalmology • Thyroid Eye Disease

Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study. (PubMed, World J Transplant) - "In this propensity score-matched analysis, alemtuzumab induction was associated with lower graft function at 12 months and higher risks of viral infection, post-transplant malignancy, and graft loss compared with basiliximab. These findings highlight the need for further studies to confirm the long-term safety and effectiveness of alemtuzumab in kidney transplantation."

Journal • Retrospective data • Cytomegalovirus Infection • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Nephrology • Oncology • Transplant Rejection • Transplantation

EXPANDING DONOR OPTIONS: RETROSPECTIVE REVIEW OF PRACTICE AND OUTCOMES FOR MISMATCHED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PAEDIATRIC ACQUIRED SEVERE APLASTIC ANAEMIA (SAA) (EBMT 2026) - "66.7% (22/33) of patients had prior immunosuppressive therapy (IST), 18.1% (6/33) developed side effects from ciclosporin use before HSCT (mainly renal impairment), and 15.2% (5/33) were receiving chelation at the time of HSCT (MUD 0/103, MRD 1/56)...In line with the national recommendation, the conditioning regimen used in 94% (32/33) consisted of Fludarabine 150mg/m2, cyclophosphamide 120 mg/kg and Alemtuzumab 0.9/1.0 mg/kg, with 81.8% (27/33) of patients receiving a combination of a calcineurin inhibitor and MMF for GVHD prophylaxis... Mismatched HSCTs, primarily using MMUD, have outcomes comparable to those of fully matched donors. TA-TMA led to treatment-related mortality in this cohort. Prospective evaluation is needed to confirm optimal placement of mismatched donors within the therapeutic algorithm for paediatric SAA."

Retrospective data • Review • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Pediatrics • Transplantation • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

LOWER GVHD RATES IN MISMATCHED DONORS WITH PTCY AS COMPARED TO MATCHED UNRELATED DONORS WITHOUT PTCY AFTER PEDIATRIC FULL BONE MARROW HSCT FOR HEMOGLOBINOPATHIES (EBMT 2026) - "The lack of HLA-matched donors for most patients drove successful HLA-mismatched unrelated and haploidentical HSCT by αβ-depletion or post-transplant cyclophosphamide (PTCy)...Conditioning was myeloablative, treosulfan-based in 89% and busulfan-based in 11%. Patients received serotherapy with anti-thymocyte globulin (92%) or alemtuzumab (8%). In addition, GvHD prophylaxis for matched patients (IRD and MUD) consisted of ciclosporin A and methotrexate 10mg/m2 on days 1, 3 and 6, whereas mismatched patients (MMUD and MMRD) predominantly received PTCy 50mg/kg on days 3 and 4 followed by ciclosporin A and mycophenolate mofetil... In the pediatric hemoglobinopathy patient cohort presented here, PTCy effectively reduced GvHD rates in HLA-mismatched HSCT to the level of HLA-identical HSCT. The significantly higher rate of GvHD in children receiving full bone marrow grafts from MUD donors demonstrates the need for additional GvHD prophylaxis in this group. In addition, pre-HSCT..."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Inflammation • Pediatrics • Sickle Cell Disease

ALEMTUZUMAB-CONDITIONED HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION CONFERS EXCELLENT SURVIVAL WITH LIMITED GVHD IN FANCONI ANEMIA (EBMT 2026) - "We present outcomes for patients with FA who underwent haploidentical transplantation with alemtuzumab-based conditioning and GVHD prophylaxis with a modified post-transplant cyclophosphamide (PTCY)...All subjects received bone marrow from haploidentical donors and conditioning with Fludarabine 150mg/m², Total Body Irradiation (TBI) 200cGy, and Alemtuzumab 0,6-0,7mg/kg. GVHD prophylaxis consisted of PTCY 50-60 mg/kg (total dose), Cyclosporin, and Mycofenolate Mofetil...Patients didn't receive letermovir prophylaxis but were successfully treated with preemptive therapy, with no evidence of CMV disease... The modified haploidentical approach incorporating alemtuzumab and PTCY achieves excellent survival outcomes in FA by decreasing rejection and TRM. The RIC approach minimizes toxicity, but careful consideration of TBI exposure and GVHD-associated malignancy risk remains a concern. The addition of alemtuzumab reduced the incidence and severity of GVHD compared to..."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Head and Neck Cancer • Immunology • Infectious Disease • Oral Cancer • Solid Tumor • Transplantation

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ATAXIA-TELANGIECTASIA - A MULTICENTER STUDY BY EBMT/IEWP (EBMT 2026) - "Conditioning regimens included reduced-intensity or non-myeloablative fludarabine-based protocols using cyclophosphamide, busulfan or treosulfan, and serotherapy (ATG or alemtuzumab). Allogeneic HSCT in A-T is feasible when using carefully selected reduced-intensity conditioning regimens. Pre-emptive alloHSCT appears effective in correcting immunodeficiency and may reduce the risk of malignancy. Outcomes in malignancy-associated HSCT were comparable when performed in complete remission."

Clinical • Ataxia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Immunology • Infectious Disease • Movement Disorders • Primary Immunodeficiency • T Acute Lymphoblastic Leukemia • Transplantation

PROSPECTIVE MULTICENTRE ANALYSIS OF FLUDARABINE EXPOSURE IN CHILDREN RECEIVING FLUDARABINE-TREOSULFAN-THIOTEPA FOR NON-SCID INBORN ERRORS OF IMMUNITY: PRELIMINARY FINDINGS FROM HAPLO+4KIDS (EBMT 2026) - "Clinical Trial Registry: Haplo+4Kids – ISRCTN11859866 - https://www.isrctn.com/ISRCTN11859866 Background: Fludarabine (FLU) has largely replaced cyclophosphamide in paediatric reduced toxicity conditioning regimens as it provides potent lymphodepletion to prevent immune mediated graft rejection while offering a more favourable toxicity profile...Serotherapy was alemtuzumab for matched unrelated donor and ATG-Grafalon for TCRab-depleted mismatched family/unrelated donor... Preliminary data indicate considerable interpatient variability in fludarabine exposure in paediatric HSCT patients. Body surface area-based dosing may lead to overexposure, particularly for infant patients. MBD without measured PK data was inaccurate in estimating individual fludarabine exposure in our study cohort, underscoring the importance of real-time therapeutic drug monitoring to enable personalised dosing to achieve a targeted drug exposure to optimise engraftment whilst minimising the risk of..."

Clinical • Bone Marrow Transplantation • Infectious Disease • Transplant Rejection

LETERMOVIR USE IN PEDIATRIC HSCT PATIENTS UNDER 12 YEARS OLD: UPDATED DATA FROM A RETROSPECTIVE MULTICENTER STUDY OF THE PDWP AND IEWP OF THE EBMT (EBMT 2026) - "Conditioning regimens included treosulfan-based (44.5%), TBI-based (32.2%), busulfan-based (15.1%), and other (8.2%). In-vivo T-cell depletion (TCD) was used in 34.2% of patients (ATG 27.4%, Campath 6.8%), and ex-vivo TCD in 11.6%.Table 1: Patient and transplant characteristics With a median follow-up of 1 year (95% CI: 0.9–1.1), the 1-year cumulative incidence of CMV reactivation was 23.8% (95% CI: 16–30) overall, 21.4% (95% CI: 13.6–29.2) during primary prophylaxis, and 32.6% (95% CI: 13.1–45) during secondary prophylaxis (Figure 1)...Among patients with CMV reactivation, one death was attributed to relapsed disease.Letermovir was well tolerated with only two patients experiencing mild gastrointestinal toxicity, and no additional significant adverse events reported.CMV reactivations were managed using standard antiviral strategies, including valganciclovir (n=10), ganciclovir (n=8), foscarnet (n=7), and cidofovir (n=1) or continued letermovir alone (n=8)... In this..."

Retrospective data • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hepatology • Immunology • Infectious Disease • Pediatrics

IMPACT OF REDUCED-INTENSITY CONDITIONING REGIMENS ON FEMALE GONADAL FUNCTION IN SICKLE CELL DISEASE (EBMT 2026) - "Patients received one of three transplant modalitiesR1 (n=11): RIC haploidentical HSCT (Antithymoglobulin (ATG), thiotepa, fludarabine, cyclophosphamide, 2Gray TBI followed by post cyclophosphamide).R2 (n=4): RIC matched related HSCT (ATG, fludarabine, cyclophosphamide, 2 Gy Total Body irradiation (TBI)).R3 (n=15): Non myeloablative matched related HSCT: Alemtuzumab, 3Gy TBI. RIC regimens can preserve ovarian function in some women with SCD undergoing HSCT. Nonetheless, persistently low AMH levels indicate diminished ovarian reserve and highlight the risk of future POI. These findings emphasize the importance of early fertility counseling, pre-transplant preservation strategies, and long-term reproductive monitoring to optimize fertility outcomes in this population."

Bone Marrow Transplantation • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • Women's Health